Clinical trials: Hepatic Malignancies
Advanced Chronic Liver Disease, Portal Hypertension
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Zinc homeostasis could play a role in advanced chronic liver disease (cACLD) and its supplementation has been linked with improvement in liver function, decrease of hepatic complications and reduction in hepatocellular carcinoma…
- Conditions
- Advanced Chronic Liver Disease, Portal Hypertension, Hepatocellular Carcinoma
- Trial name
- NCT06434753
- Testing
- Zinc Acexamate
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Hepatic Impairment, Healthy Volunteers
A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic Impairment
The purpose of this study is to assess the drug levels of a single oral dose of repotrectinib in participants with moderate and severe HI, and in healthy matched control participants with normal hepatic function.
- Trial name
- NCT06352528
- Testing
- Repotrectinib
- Where
- 3 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Cholangiocarcinoma
Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma
The study aims to valide a proof of a concept of the proteomic profiling as a diagnostic tool for bile duct stenosis suspicious of cholangiocarcinoma.
- Trial name
- PROFI-CHOL (NCT06780553)
- Testing
- Proteomic profiling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Bordeaux
Hepatic Neoplasms, Biliary Tract Neoplasms
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy.
- Conditions
- Hepatic Neoplasms, Biliary Tract Neoplasms, Pancreatic Neoplasms
- Trial name
- PReHeBP (NCT02784353)
- Testing
- Perioperative rehabilitation program, Conventional
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Asan Medical Center
Stage IIIA Hepatocellular Carcinoma
Radiotherapy Combined With TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma
The purpose of this clinical research study is to investigate the efficacy and safety of Radiotherapy Combined with TKI and Anti-PD-1 Antibody for Stage IIIA Hepatocellular Carcinoma with Portal Vein Tumor Thrombus(PVTT).
- Trial name
- NCT06061445
- Testing
- Radiotherapy combined with TKI and Anti-PD-1 Antibody
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fujian Cancer Hospital
Liver Cancer
Safety and Efficacy of Transarterial ICG Fluorescence-Guided Laparoscopic Anatomical Liver Resection
This multicenter, ambispective cohort study evaluates the safety and efficacy of trans-arterial Indocyanine Green (ICG) fluorescence-guided laparoscopic liver watershed resection for Hepatocellular Carcinoma (HCC).
- Trial name
- NCT07295275
- Testing
- Laparoscopic Anatomical Liver Resection (guided by transarterial injection of ICG)
- Where
- 3 sites in China
- Volunteers
- 200 people
- Sponsor
- West China Hospital
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Solid Tumors
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects
A study to assess the pharmacokinetics, safety and tolerability of Selumetinib (AZD6244, ARRY-142886) in patients with hepatic impairment and healthy subjects.
- Trial name
- NCT02063230
- Testing
- Selumetinib 50mg, Selumetinib 25mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma (HCC) Prognosis, Contrast-enhanced Ultrasound
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases.
- Trial name
- NCT07600346
- Testing
- Contrast-Enhanced Ultrasound
- Volunteers
- 105 people
- Sponsor
- The First Hospital of Jilin University
Colorectal Cancer
Treatment Outcomes of Hepatic Metastasis After FOLFOX-4 Therapy
The role of surgical resection in the subset of patients with resectable hepatic metastases converted from initially non-resectable liver metastasis was still not clearly established.
- Trial name
- NCT00610636
- Testing
- Hepatic resection
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma (HCC)
Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)
Intra-arterial (IA) therapy is generally used to treat HCC tumors that are too extensive to excise or treat with potentially curative local therapy.
- Trial name
- NCT04601428
- Testing
- IA therapy of HCC with CSR02-Fab-TF
- Where
- 4 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Koo Foundation Sun Yat-Sen Cancer Center
Hepatocellular Carcinoma, Adjuvant Therapy
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative…
- Trial name
- NCT04981665
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Intrahepatic Cholangiocarcinoma
A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
Compare the efficacy of adjuvant chemotherapy with Cisplatin or Carboplatin and Gemcitabine versus Gemcitabine in patients with resected or ablated intra-hepatic cholangiocarcinoma.
- Trial name
- NCT03081039
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- United States
- Sponsor
- University of Louisville
Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
The present study aimed to assess the effectiveness of the combination treatment of Atezolizumab/Bevacizumab, transcatheter arterial chemoembolization (TACE) and I-125 Seeds Brachytherapy (TACE-AB-I) in patients with advanced…
- Conditions
- Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
- Trial name
- NCT05984511
- Testing
- I-125 Seeds Brachytherapy in PVTT, Transcatheter arterial chemoembolization, Atezolizumab plus Bevacizumab
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Metastatic Cancer, Congestive Heart Failure
Reducing Disparities in the Quality of Advance Care Planning for Older Adults
This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community.
- Conditions
- Metastatic Cancer, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease, Parkinson Disease
- Trial name
- EQUALACP (NCT03516994)
- Testing
- Respecting Choices First Steps, Five Wishes Form
- Where
- 4 sites in United States
- Volunteers
- 790 people
- Sponsor
- Duke University
Liver Tumor, Hepatic Fibrosis
Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study
To evaluate the diagnostic performance of two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection, using resected tissue…
- Trial name
- NCT02958592
- Testing
- two-dimensional shear-wave elastography (SWE)
- Volunteers
- 121 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma
Hepatocellular carcinoma is one of the most common solid malignant tumors. The prognosis of unresectable hepatocellular carcinoma is very poor.
- Trial name
- NCT05760430
- Testing
- PVE+cTACE+Camrelizumab+Apatinib, cTACE+Atirizumab+Bevacizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
Tislelizumab Combined With IMRT Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT
Due to the biological characteristics and liver anatomical characteristics of liver cancer, liver cancer cells easily invade the vascular system, especially the portal venous system, forming portal vein tumor thrombus (PVTT) …
- Trial name
- NCT04850157
- Testing
- Tislelizumab, IMRT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Chemoembolization
TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve
TACE is frequently offered to patients with baseline hepatic dysfunction with the purpose of diminishing hepatic tumor burden while patients await transplantation.
- Trial name
- NCT02147301
- Testing
- LC Bead
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.